Publication

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia

de Boer, P. T., Kelso, J. K., Halder, N., Nguyen, T-P-L., Moyes, J., Cohen, C., Barr, I. G., Postma, M. J. & Milne, G. J., 8-Feb-2018, In : Vaccine. 36, 7, p. 997-1007 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

de Boer, P. T., Kelso, J. K., Halder, N., Nguyen, T-P-L., Moyes, J., Cohen, C., Barr, I. G., Postma, M. J., & Milne, G. J. (2018). The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia. Vaccine, 36(7), 997-1007. https://doi.org/10.1016/j.vaccine.2017.12.073

Author

de Boer, Pieter T ; Kelso, Joel K ; Halder, Nilimesh ; Nguyen, Thi-Phuong-Lan ; Moyes, Jocelyn ; Cohen, Cheryl ; Barr, Ian G ; Postma, Maarten J ; Milne, George J. / The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia. In: Vaccine. 2018 ; Vol. 36, No. 7. pp. 997-1007.

Harvard

de Boer, PT, Kelso, JK, Halder, N, Nguyen, T-P-L, Moyes, J, Cohen, C, Barr, IG, Postma, MJ & Milne, GJ 2018, 'The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia', Vaccine, vol. 36, no. 7, pp. 997-1007. https://doi.org/10.1016/j.vaccine.2017.12.073

Standard

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia. / de Boer, Pieter T; Kelso, Joel K; Halder, Nilimesh; Nguyen, Thi-Phuong-Lan; Moyes, Jocelyn; Cohen, Cheryl; Barr, Ian G; Postma, Maarten J; Milne, George J.

In: Vaccine, Vol. 36, No. 7, 08.02.2018, p. 997-1007.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

de Boer PT, Kelso JK, Halder N, Nguyen T-P-L, Moyes J, Cohen C et al. The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia. Vaccine. 2018 Feb 8;36(7):997-1007. https://doi.org/10.1016/j.vaccine.2017.12.073


BibTeX

@article{1e0a42157c7f4c379473e6c001e0fef0,
title = "The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia",
abstract = "BACKGROUND: To inform national healthcare authorities whether quadrivalent influenza vaccines (QIVs) provide better value for money than trivalent influenza vaccines (TIVs), we assessed the cost-effectiveness of TIV and QIV in low-and-middle income communities based in South Africa and Vietnam and contrasted these findings with those from a high-income community in Australia.METHODS: Individual based dynamic simulation models were interfaced with a health economic analysis model to estimate the cost-effectiveness of vaccinating 15% of the population with QIV or TIV in each community over the period 2003-2013. Vaccination was prioritized for HIV-infected individuals, before elderly aged 65+ years and young children. Country or region-specific data on influenza-strain circulation, clinical outcomes and costs were obtained from published sources. The societal perspective was used and outcomes were expressed in International$ (I$) per quality-adjusted life-year (QALY) gained.RESULTS: When compared with TIV, we found that QIV would provide a greater reduction in influenza-related morbidity in communities in South Africa and Vietnam as compared with Australia. The incremental cost-effectiveness ratio of QIV versus TIV was estimated at I$4183/QALY in South Africa, I$1505/QALY in Vietnam and I$80,966/QALY in Australia.CONCLUSIONS: The cost-effectiveness of QIV varied between communities due to differences in influenza epidemiology, comorbidities, and unit costs. Whether TIV or QIV is the most cost-effective alternative heavily depends on influenza B burden among subpopulations targeted forvaccination in addition to country-specific willingness-to-pay thresholds and budgetary impact.",
keywords = "Influenza, Cost-effectiveness, Vaccination, Trivalent, Quadrivalent, Dynamic transmission model, MIDDLE-INCOME COUNTRIES, PANDEMIC INFLUENZA, UNITED-STATES, VACCINES, SURVEILLANCE, EFFICACY, COHORT, EPIDEMIOLOGY, IMMUNIZATION, CHILDREN",
author = "{de Boer}, {Pieter T} and Kelso, {Joel K} and Nilimesh Halder and Thi-Phuong-Lan Nguyen and Jocelyn Moyes and Cheryl Cohen and Barr, {Ian G} and Postma, {Maarten J} and Milne, {George J}",
note = "Copyright {\textcopyright} 2017. Published by Elsevier Ltd.",
year = "2018",
month = feb,
day = "8",
doi = "10.1016/j.vaccine.2017.12.073",
language = "English",
volume = "36",
pages = "997--1007",
journal = "Vaccine",
issn = "0264-410X",
publisher = "ELSEVIER SCI LTD",
number = "7",

}

RIS

TY - JOUR

T1 - The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia

AU - de Boer, Pieter T

AU - Kelso, Joel K

AU - Halder, Nilimesh

AU - Nguyen, Thi-Phuong-Lan

AU - Moyes, Jocelyn

AU - Cohen, Cheryl

AU - Barr, Ian G

AU - Postma, Maarten J

AU - Milne, George J

N1 - Copyright © 2017. Published by Elsevier Ltd.

PY - 2018/2/8

Y1 - 2018/2/8

N2 - BACKGROUND: To inform national healthcare authorities whether quadrivalent influenza vaccines (QIVs) provide better value for money than trivalent influenza vaccines (TIVs), we assessed the cost-effectiveness of TIV and QIV in low-and-middle income communities based in South Africa and Vietnam and contrasted these findings with those from a high-income community in Australia.METHODS: Individual based dynamic simulation models were interfaced with a health economic analysis model to estimate the cost-effectiveness of vaccinating 15% of the population with QIV or TIV in each community over the period 2003-2013. Vaccination was prioritized for HIV-infected individuals, before elderly aged 65+ years and young children. Country or region-specific data on influenza-strain circulation, clinical outcomes and costs were obtained from published sources. The societal perspective was used and outcomes were expressed in International$ (I$) per quality-adjusted life-year (QALY) gained.RESULTS: When compared with TIV, we found that QIV would provide a greater reduction in influenza-related morbidity in communities in South Africa and Vietnam as compared with Australia. The incremental cost-effectiveness ratio of QIV versus TIV was estimated at I$4183/QALY in South Africa, I$1505/QALY in Vietnam and I$80,966/QALY in Australia.CONCLUSIONS: The cost-effectiveness of QIV varied between communities due to differences in influenza epidemiology, comorbidities, and unit costs. Whether TIV or QIV is the most cost-effective alternative heavily depends on influenza B burden among subpopulations targeted forvaccination in addition to country-specific willingness-to-pay thresholds and budgetary impact.

AB - BACKGROUND: To inform national healthcare authorities whether quadrivalent influenza vaccines (QIVs) provide better value for money than trivalent influenza vaccines (TIVs), we assessed the cost-effectiveness of TIV and QIV in low-and-middle income communities based in South Africa and Vietnam and contrasted these findings with those from a high-income community in Australia.METHODS: Individual based dynamic simulation models were interfaced with a health economic analysis model to estimate the cost-effectiveness of vaccinating 15% of the population with QIV or TIV in each community over the period 2003-2013. Vaccination was prioritized for HIV-infected individuals, before elderly aged 65+ years and young children. Country or region-specific data on influenza-strain circulation, clinical outcomes and costs were obtained from published sources. The societal perspective was used and outcomes were expressed in International$ (I$) per quality-adjusted life-year (QALY) gained.RESULTS: When compared with TIV, we found that QIV would provide a greater reduction in influenza-related morbidity in communities in South Africa and Vietnam as compared with Australia. The incremental cost-effectiveness ratio of QIV versus TIV was estimated at I$4183/QALY in South Africa, I$1505/QALY in Vietnam and I$80,966/QALY in Australia.CONCLUSIONS: The cost-effectiveness of QIV varied between communities due to differences in influenza epidemiology, comorbidities, and unit costs. Whether TIV or QIV is the most cost-effective alternative heavily depends on influenza B burden among subpopulations targeted forvaccination in addition to country-specific willingness-to-pay thresholds and budgetary impact.

KW - Influenza

KW - Cost-effectiveness

KW - Vaccination

KW - Trivalent

KW - Quadrivalent

KW - Dynamic transmission model

KW - MIDDLE-INCOME COUNTRIES

KW - PANDEMIC INFLUENZA

KW - UNITED-STATES

KW - VACCINES

KW - SURVEILLANCE

KW - EFFICACY

KW - COHORT

KW - EPIDEMIOLOGY

KW - IMMUNIZATION

KW - CHILDREN

U2 - 10.1016/j.vaccine.2017.12.073

DO - 10.1016/j.vaccine.2017.12.073

M3 - Article

C2 - 29373192

VL - 36

SP - 997

EP - 1007

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 7

ER -

ID: 53662771